ERBB2 and breast carcinoma: Inthis prospective cohort study, we have found that age, HBP, BMI, baseline LVEF,LVESV, Sm and Em wave, LA, E/A and NT-proBNP are not predictors oftrastuzumab-related cardiac dysfunction in HER-2 positive breast cancer patientsundergoing post-low dose anthracycline adjuvant trastuzumab therapy.